Aglaia

Aglaia Oncology Funds is a Dutch venture capital firm specializing in early-stage investments in oncology. Founded in 2004, the firm focuses on groundbreaking technologies that have the potential to transform cancer diagnosis and treatment. Aglaia actively collaborates with scientists and management teams to translate high-potential research into commercially and clinically successful products. Aglaia's portfolio includes notable companies such as Cristal Therapeutics, Inthera Bioscience, Macrophage Pharma, Mimetas, Modra Pharmaceuticals, and Sapreme Technologies. The firm has also seen successful exits with companies like Merus and Synthon. The team at Aglaia is led by partners Eric van der Putten, Karl Rothweiler, Mark Krul, and supported by a strong advisory board comprising experts in oncology and biotech, including Alan Barge, Sjoerd van der Burg, and Kees Melief. This team brings deep expertise in cancer research and drug development, ensuring that their portfolio companies receive comprehensive strategic support. Aglaia Oncology Funds emphasizes impact investing, aiming to generate both financial and social returns by advancing innovative cancer treatments.